252,700 Shares in Treace Medical Concepts, Inc. $TMCI Bought by Nuveen LLC

Nuveen LLC acquired a new stake in Treace Medical Concepts, Inc. (NASDAQ:TMCI) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 252,700 shares of the company’s stock, valued at approximately $2,120,000. Nuveen LLC owned 0.40% of Treace Medical Concepts as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Treace Medical Concepts by 1.1% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 244,800 shares of the company’s stock valued at $2,054,000 after acquiring an additional 2,645 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Treace Medical Concepts by 5.8% in the first quarter. Rhumbline Advisers now owns 69,916 shares of the company’s stock valued at $587,000 after buying an additional 3,843 shares in the last quarter. Lisanti Capital Growth LLC acquired a new position in Treace Medical Concepts during the first quarter worth $2,116,000. Arcadia Wealth Management Inc. purchased a new position in Treace Medical Concepts in the first quarter worth $1,762,000. Finally, Nuveen Asset Management LLC lifted its holdings in Treace Medical Concepts by 11.4% in the fourth quarter. Nuveen Asset Management LLC now owns 472,840 shares of the company’s stock valued at $3,518,000 after acquiring an additional 48,525 shares during the period. Hedge funds and other institutional investors own 84.08% of the company’s stock.

Treace Medical Concepts Trading Down 0.8%

Shares of TMCI stock opened at $7.34 on Friday. The company has a market capitalization of $463.69 million, a price-to-earnings ratio of -9.29 and a beta of 0.68. The company has a current ratio of 3.52, a quick ratio of 2.51 and a debt-to-equity ratio of 0.55. The firm has a 50-day moving average price of $6.22 and a 200 day moving average price of $7.00. Treace Medical Concepts, Inc. has a twelve month low of $4.54 and a twelve month high of $10.79.

Treace Medical Concepts (NASDAQ:TMCI) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.01. Treace Medical Concepts had a negative net margin of 23.01% and a negative return on equity of 46.76%. The business had revenue of $47.39 million during the quarter, compared to the consensus estimate of $47.08 million. Treace Medical Concepts has set its FY 2025 guidance at EPS. Research analysts forecast that Treace Medical Concepts, Inc. will post -0.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on TMCI shares. UBS Group reiterated a “neutral” rating and issued a $6.50 price target (down previously from $8.60) on shares of Treace Medical Concepts in a report on Friday, August 8th. Stifel Nicolaus reduced their price target on shares of Treace Medical Concepts from $9.00 to $6.00 and set a “hold” rating for the company in a research report on Friday, August 8th. Two research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $9.83.

Treace Medical Concepts Company Profile

Treace Medical Concepts, Inc, a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity.